"}

Eculizumab (anti-Complement C5) - Primary antibody, specific to C5, >95%, Human IgG2+Human IgG4, INHIBITOR of Complement C5 inhibitor, INHIBITOR of Complement C5 inhibitor

In stock
SKU
Ab170870
Grouped product items
Product Name Qty
[Ab170870-100μg] Eculizumab (anti-Complement C5) (100μg)
€163.05
[Ab170870-1mg] Eculizumab (anti-Complement C5) (1mg)
€649.85
[Ab170870-5mg] Eculizumab (anti-Complement C5) (5mg)
€2,443.47
[Ab170870-10mg] Eculizumab (anti-Complement C5) (10mg)
€3,231.37

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2+Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Eculizumab (anti-Complement C5) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab (anti-Complement C5) inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab (anti-Complement C5) has the potential for haemolysis research.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

More Information

More Information
Endotoxin Concentration<1.0 EU/mg
TargetC5
PubChem CID3081333
Pubchem Sid528764377
Gene Id727
Accession #P01031
Gene SymbolC5
SynonymsAnaphylatoxin C5a analog antibody | C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 antibody | C5 antibody | C5a anaphylatoxin antibody | C5a antibody | C5b antibody | CO5_HUMAN antibody | Complement C5 alpha'' chain antibody | Complemen
Specifications & PurityCarrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
SpecificityC5
IsotypeHuman IgG2+Human IgG4
Light Chain Typekappa
SDS-PAGE26.1 kDa (Light Chain) & 51.6 kDa (Heavy Chain), under reducing conditions; 165.6 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
ConcentrationSee COA
CAS219685-50-4
Product Description

Eculizumab (anti-Complement C5) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab (anti-Complement C5) inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab (anti-Complement C5) has the potential for haemolysis research.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

FormLiquid
StorageStore at -80°C,Avoid repeated freezing and thawing
Shipped InDry ice packs + Cold packs
Stability And StorageStore at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Reviews

Customer Reviews

Alternative Products

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.

Copyright © 2023-present Aladdin Scientific Corp All rights reserved.